Advertisement

Neuropathy in Diabetes

  • Michael RubinEmail author
  • Russell L. Chin
Reference work entry

Abstract

Diabetes is the most common cause of sensory polyneuropathy in the United States, and can cause any type of focal, multifocal, or polyneuropathy. Etiology of neuropathy in diabetes continues to be an area of active investigation and is likely multifactorial. Treatment remains, first and foremost, control of blood glucose levels to the best extent possible. Otherwise, treatment is symptomatic in nature. At this time, no agents are available to promote nerve regeneration.

Keywords

Polyneuropathy Mononeuropathy Ischemia Autoimmune Anticonvulsants Tricyclic antidepressants 

References

  1. 1.
  2. 2.
  3. 3.
    Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabetes Care. 2011;34:2220–4.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Selvarajah D, Cash T, Sankar A. The contributors of emotional distress in painful diabetic neuropathy. Diab Vasc Dis Res. 2014. doi:10.1177/1479164114522135.Google Scholar
  5. 5.
    Selvarajah D, Wilkinson ID, Emery CJ, Harris ND, Shaw PJ, Witte DR, Griffiths PD, Tesfaye S. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care. 2006;29:2664–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Wessels AM, Rombouts SA, Simsek S, Kuijer JP, Kostense PJ, Barkhof F, Scheltens P, Snoek FJ, Heine RJ. Microvascular disease in type 1 diabetes alters brain activation: a functional magnetic resonance imaging study. Diabetes. 2006;55:334–40.CrossRefPubMedGoogle Scholar
  7. 7.
    Moran C, Beare R, Phan TG, et al. Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015;85:1123–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Malik RA, Kallinikos P, Abbott CA, van Schie CH, Morgan P, Efron N, Boulton AJ. Corneal confocal microscopy: a non-invasive surrogate of nerve fiber damage and repair in diabetic patients. Diabetologia. 2003;46:683–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Pittenger GL, Ray M, Burcus NI, McNulty P, Basta B, Vinik AI. Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients. Diabetes Care. 2004;27:1974–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  11. 11.
    Francis G, Martinez J, Liu W, Nguyen T, Ayer A, Fine J, Zochodne D, Hanson LR, Frey 2nd WH, Toth C. Intranasal insulin ameliorates experimental diabetic neuropathy. Diabetes. 2009;58:934–45.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wu X, Zha D, Xiang G, Zhang B, Xiao SY, Jia R. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats. Cytokine. 2006;36:229–36.CrossRefPubMedGoogle Scholar
  13. 13.
    Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diab Med. 2000;17:181–9.CrossRefGoogle Scholar
  14. 14.
    Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm Jr RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRefPubMedGoogle Scholar
  15. 15.
    Wile DJ, Toth C. Association of metformin, elevated homocysteine, methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy. Diabetes Care. 2010;33:156–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 1983;308:119–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Boulton AJM, Levin SR, Comstock JP. A multicenter trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia. 1990;33:433–6.CrossRefGoogle Scholar
  18. 18.
    Dyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myoinositol related to sural nerve morphometry. Ann Neurol. 1980;8:590–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamagishi S, Masuta N, Okamoto K, Yagihashi S. Alterations of protein kinase C activity in the peripheral nerve of STZ-induced diabetic mice overexpressing human aldose reductase (abstract). Diabetes. 2001;50:A190.CrossRefGoogle Scholar
  20. 20.
    Yamagishi S, Uehara K, Otsuki S, Yagihashi S. Differential influence of increased polyol pathway on protein kinase C expressions between endoneurial and epineurial tissues in diabetic mice. J Neurochem. 2003;87:497–507.CrossRefPubMedGoogle Scholar
  21. 21.
    Watkins PJ, Gayle C, Alsanjari N, et al. Severe sensory autonomic neuropathy and endocrinopathy in insulin dependent diabetes. Q J Med. 1999;88:795–804.Google Scholar
  22. 22.
    Kelkar P, Masood M, Parry GJ. Distinctive pathologic findings in proximal diabetic neuropathy (diabetic amyotrophy). Neurology. 2000;55:83–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Halestrap AP. Calcium, mitochondria, and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34:232–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Li X-G, Zochodne DW. Microvacuolar neuronopathy is a post-mortem artifact of sensory neurons. J Neurocytol. 2003;32:393–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Yagihashi S, Kamijo M, Ido Y, et al. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes. 1990;39:690–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Xu QG, Li X-Q, Kotecha SA, et al. Insulin as an in vivo growth factor. Exp Neurol. 2004;188:43–51.CrossRefPubMedGoogle Scholar
  27. 27.
    Toth C, Brussee V, Zochodne DW. Remote neurotrophic support of epidermal nerve fibers in experimental diabetes. Diabetologia. 2006;49:1081–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Windebank AJ, Feldman EL. Diabetes and the nervous system. In: Aminoff M, editor. Neurology and general medicine. 3rd ed. Philadelphia: Churchill Livingstone; 2001.Google Scholar
  29. 29.
    Melton III LJ, Dyck PJ. Epidemiology. In: Dyck PJ, Thomas PK, et al., editors. Diabetic neuropathy. 2nd ed. Philadelphia: WB Saunders; 1999. p. 239–52.Google Scholar
  30. 30.
    Pasnoor M, Dimachkie MM, Kluding P, Barohn RJ. Diabetic neuropathy part 1. Neurol Clin. 2013;31:425–45.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dyck PJ, Karnes JL, O’Brien PC, et al. The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity. Neurology. 1992;42:1164–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Niakan E, Harati Y. Sympathetic skin response in diabetic peripheral neuropathy. Muscle Nerve. 1988;11:261–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy. Diabetes Care. 2004;27:2942–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med. 1980;49:95–108.PubMedGoogle Scholar
  35. 35.
    Aronson D. Pharmacologic modulation of autonomic tone: implications for the diabetic patient. Diabetologia. 1997;40:476–81.CrossRefPubMedGoogle Scholar
  36. 36.
    Schnell O, Schwarz A, Becker DM, Standl E. Autoantibodies against autonomic nervous tissues in type 2 diabetes. Exp Clin Endocrinol Diabetes. 2000;108:181–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Wein TH, Albers JW. Diabetic neuropathies. Phys Med Rehabil Clin N Am. 2001;12(2):307–20.PubMedGoogle Scholar
  38. 38.
    Tavaloki M, Begum P, McLaughlin J, Malik RA. Corneal confocal microscopy for the diagnosis of diabetic autonomic neuropathy. Muscle Nerve. 2015;52:363–70.CrossRefGoogle Scholar
  39. 39.
    Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc. 1997;72:1123–32.CrossRefPubMedGoogle Scholar
  40. 40.
    Said G, Goulon-Goeau C, Lacroix C, Moulonguet A. Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol. 1994;35:559–69.CrossRefPubMedGoogle Scholar
  41. 41.
    Dyck PJB, Windebank AJ. Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve. 2002;25:477–91.CrossRefPubMedGoogle Scholar
  42. 42.
    Sinnreich M, Taylor BV, Dyck PJB. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005;11:63–79.CrossRefPubMedGoogle Scholar
  43. 43.
    Kawagashira Y, Watanabe H, Oki Y, et al. Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:899–901.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Schaublin GA, Michet Jr CJ, Dyck PJ, Burns TM. An update on the classification and treatment of vasculitic neuropathy. Lancet Neurol. 2005;4:853–65.CrossRefPubMedGoogle Scholar
  45. 45.
    Dyck PJB, O’Brien P, Bosch EP, et al. The multi-centre, double-blind controlled trial of IV methylprednisolone in diabetic lumbosacral radiculoplexus neuropathy. Neurology. 2006;66(5 Suppl 2):A191.Google Scholar
  46. 46.
    Stewart JD. Diabetic truncal neuropathy: topography of the sensory deficit. Ann Neurol. 1989;25:233–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Sun SF, Streib EW. Diabetic thoracoabdominal neuropathy: clinical and electrodiagnostic features. Ann Neuro. 1981;9:75.CrossRefGoogle Scholar
  48. 48.
    Longstreth GF. Diabetic thoracic polyradiculopathy. Best Pract Res Clin Gastroenterol. 2005;19:275–81.CrossRefPubMedGoogle Scholar
  49. 49.
    Katz JS, Saperstein DS, Wolfe G, et al. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve. 2001;24:794–8.CrossRefPubMedGoogle Scholar
  50. 50.
    Goldstein JE, Cogan DG. Diabetic ophthalmoplegia with special reference to the pupil. Arch Ophthalmol. 1960;64:592.CrossRefPubMedGoogle Scholar
  51. 51.
    Jacobson DM. Pupil involvement in patients with diabetes-associated oculomotor nerve palsy. Arch Ophthalmol. 1998;116:723–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Richards BW, Jones FR, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear, and abducens cranial nerves. Am J Ophthalmol. 1992;113:489.CrossRefPubMedGoogle Scholar
  53. 53.
    Kanazawa A, Haginomori S, Takamaki A, et al. Prognosis for Bell’s palsy: a comparison of diabetic and nondiabetic patients. Acta Otolaryngol. 2007;127:888–91.CrossRefPubMedGoogle Scholar
  54. 54.
    Stamboulis E, Vassilopoulos D, Kalfakis N. Symptomatic focal mononeuropathies in diabetic patients: increased or not? J Neurol. 2005;252:448–52.CrossRefPubMedGoogle Scholar
  55. 55.
    Dahlin LB, Meiri KF, McLean WG, et al. Effects of nerve compression on fast axonal transport in streptozotocin-induced diabetes mellitus. Diabetologia. 1986;29:181–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Ozkul Y, Sabuncu T, Kocabey Y, et al. Outcomes of carpal tunnel release in diabetic and non-diabetic patients. Acta Neurol Scand. 2002;106:168–72.CrossRefPubMedGoogle Scholar
  57. 57.
    Shahani B, Spalding JMK. Diabetes mellitus presenting with bilateral foot-drop. Lancet. 1969;2:930–1.CrossRefPubMedGoogle Scholar
  58. 58.
    Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice. 3rd ed. New York: Oxford University Press; 2001.Google Scholar
  59. 59.
    Umapathi T, Tan WL, Loke SC, et al. Intraepidermal nerve fiber density as a marker of early diabetic neuropathy. Muscle Nerve. 2007;35:591–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Mehra S, Tavakoli M, Kallinikos PA, et al. Corneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetes. Diabetes Care. 2007;30:2608–12.CrossRefPubMedGoogle Scholar
  61. 61.
    Pham M, Oikonomou D, Hornung B, et al. MR neurography detects diabetic neuropathy early and with proximal predominance. Ann Neurol. doi:10.1002/ana.24524.Google Scholar
  62. 62.
    Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann Neurol. 1997;42:727–36.CrossRefPubMedGoogle Scholar
  63. 63.
    Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294–9.CrossRefPubMedGoogle Scholar
  64. 64.
    Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054–60.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Bril V, Buchanan RA. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care. 2006;29:68–72.CrossRefPubMedGoogle Scholar
  66. 66.
    Vinik AI, Bril V, Kempler P, et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther. 2005;27:1164–80.CrossRefPubMedGoogle Scholar
  67. 67.
    Keen H, Payan J, Allawi J, et al. Treatment of diabetic neuropathy with gamma-linolenic acid. The gamma-Linolenic Acid Multicenter Trial Group. Diabetes Care. 1993;16:8–15.CrossRefPubMedGoogle Scholar
  68. 68.
    Zochodne DW. Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve. 2007;36:144–66.CrossRefPubMedGoogle Scholar
  69. 69.
    Ziegler D. Treatment of diabetic polyneuropathy. Ann N Y Acad Sci. 2006;1084:250–66.CrossRefPubMedGoogle Scholar
  70. 70.
    Vinik A. Clinical review: use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. J Clin Endocrinol Metab. 2005;90:4936–45.CrossRefPubMedGoogle Scholar
  71. 71.
    McKeage K. Treatment options for the management of diabetic painful neuropathy: best current evidence. Curr Opin Neurol. 2007;20(5):553–7.CrossRefPubMedGoogle Scholar
  72. 72.
    Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927–34.CrossRefPubMedGoogle Scholar
  73. 73.
    Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.CrossRefPubMedGoogle Scholar
  74. 74.
    Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48:817–23.CrossRefPubMedGoogle Scholar
  75. 75.
    Weintraub MI, Herrmann DN, Smith AG, et al. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil. 2009;90(7):1102–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Kluding PM, Pasnoor M, Singh R, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabet Complications. 2012;26(5):424–9.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of NeurologyWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Peripheral Neuropathy CenterWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations